Arcus Biosciences (RCUS) Common Equity (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Common Equity of $524.0 million for Q1 2026, down 1.32% year-over-year from $531.0 million in Q1 2025, and down 16.96% quarter-over-quarter from $631.0 million in Q4 2025.
Arcus Biosciences (RCUS) Common Equity (2017 - 2026) Analysis & Trends
Arcus Biosciences' Common Equity history runs 10 years deep, the most recent figure standing at $524.0 million for Q1 2026.
- In Q1 2026, Common Equity fell 1.32% year-over-year to $524.0 million; the TTM figure through Mar 2026 stood at $524.0 million (down 1.32% YoY), while the FY2025 annual figure was $631.0 million, up 30.1% from the prior year.
- Common Equity for Q1 2026 stood at $524.0 million, down from $631.0 million in the prior quarter.
- The five-year high for Common Equity was $797.0 million in Q1 2022, with the low at $436.0 million in Q3 2025.
- The 5-year median for Common Equity is $566.0 million (2023), against an average of $594.8 million.
- The sharpest annual moves came in 2023 and 2025: Common Equity fell 29.68% in 2023, then soared 30.1% in 2025.
- Arcus Biosciences' Common Equity stood at $657.0 million in 2022, then declined by 29.68% to $462.0 million in 2023, then climbed by 4.98% to $485.0 million in 2024, then surged by 30.1% to $631.0 million in 2025, then fell by 16.96% to $524.0 million in 2026.
- Business Quant data shows RCUS's Common Equity at $524.0 million in Q1 2026, $631.0 million in Q4 2025, and $436.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 464.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 464.00 Mn |
| Mar 31, 2026 | 524.00 Mn |
| Dec 31, 2025 | 631.00 Mn |
| Sep 30, 2025 | 436.00 Mn |
| Jun 30, 2025 | 549.00 Mn |
| Mar 31, 2025 | 531.00 Mn |
| Dec 31, 2024 | 485.00 Mn |
| Sep 30, 2024 | 565.00 Mn |
| Jun 30, 2024 | 635.00 Mn |
| Mar 31, 2024 | 707.00 Mn |
| Dec 31, 2023 | 462.00 Mn |
| Sep 30, 2023 | 520.00 Mn |
| Jun 30, 2023 | 566.00 Mn |
| Mar 31, 2023 | 600.00 Mn |
| Dec 31, 2022 | 657.00 Mn |
| Sep 30, 2022 | 699.00 Mn |
| Jun 30, 2022 | 747.00 Mn |
| Mar 31, 2022 | 797.00 Mn |
| Dec 31, 2021 | 842.00 Mn |
| Sep 30, 2021 | 542.61 Mn |